Editorial commentary: platelet-rich plasma in ACL surgery

Area of Science:

• Orthopedic Surgery
• Regenerative Medicine
• Biologics in Sports Medicine

Background:

• Platelet-rich plasma (PRP) is a concentration of platelets derived from autologous blood, intended to accelerate healing of soft tissues.
• Current literature lacks robust evidence supporting PRP treatment's efficacy in improving clinical outcomes for anterior cruciate ligament (ACL) reconstruction.
• The heterogeneity of PRP preparations and variability in study methodologies present significant challenges in interpreting existing clinical data.

Discussion:

• The inconsistent findings regarding PRP efficacy in ACL surgery may stem from the diverse methods used to prepare PRP, leading to variations in growth factor concentrations.
• Numerous confounding variables, including surgical techniques, patient factors, and rehabilitation protocols, complicate the assessment of PRP's isolated effect on ACL outcomes.
• PRP represents one of many biologic agents being investigated for orthopedic applications, and its role alongside other stimulants requires further elucidation.

Key Insights:

• Existing clinical evidence does not support the routine use of PRP to improve ACL surgical outcomes.
• Variability in PRP preparation methods and study designs are major limitations in current research.
• The potential benefits of PRP for ACL surgery remain largely unproven due to insufficient high-quality clinical data.

Outlook:

• Future research should focus on standardizing PRP preparation protocols and conducting well-designed, large-scale clinical trials for ACL applications.
• Investigating the synergistic effects of PRP with other biologic agents could offer new therapeutic avenues.
• Further studies are necessary to determine the specific patient populations or surgical scenarios where PRP might provide a demonstrable benefit in ACL reconstruction.